Secondary Anticoagulation Use in Patients < 21 Years Old following Primary Anticoagulant Treatment for Provoked Venous Thromboembolism: Findings from the Kids-DOTT Trial.

Autor: Wilson HP; Department of Pediatrics, University of Alabama at Birmingham Heersink School of Medicine and Children's of Alabama, Birmingham, Alabama., Mosha M; Department of Health Informatics, Data Coordinating Center for Pediatric Multicenter Studies, Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida., Miller A; Department of Health Informatics, Data Coordinating Center for Pediatric Multicenter Studies, Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida., Betensky M; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Pediatrics, Johns Hopkins All Children's Hospital, St. Petersburg, Florida., Amankwah E; Department of Health Informatics, Data Coordinating Center for Pediatric Multicenter Studies, Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida.; Department of Pediatrics, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Fargo J; Department of Pediatrics, Feinberg School of Medicine at Northwestern University, Chicago, Illinois.; Division of Hematology, Oncology and Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois., Thornburg CD; Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California.; Department of Pediatrics, Rady Children's Hospital San Diego, San Diego, California., Tarango C; Department of Pediatrics, University of Cincinnati College of Medicine and Cincinnati Children's Hospital, Cincinnati, Ohio., Acharya S; Department of Pediatrics, Cohen Children's Medical Center, Northwell Health, New Hyde Park, New York., Male C; Department of Pediatrics, Medical University of Vienna, Vienna, Austria., Narang S; Department of Pediatrics, Newark Beth Israel Medical Center, Rutgers University, Newark, New Jersey., Schulman S; Department of Medicine, McMaster University, Hamilton, Ontario, Canada., Goldenberg NA; Department of Health Informatics, Data Coordinating Center for Pediatric Multicenter Studies, Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida.; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jazyk: angličtina
Zdroj: Seminars in thrombosis and hemostasis [Semin Thromb Hemost] 2024 Sep 19. Date of Electronic Publication: 2024 Sep 19.
DOI: 10.1055/s-0044-1790572
Abstrakt: Competing Interests: H.P.W. reported receiving personal fees from Octapharma for role on data safety monitoring board and grant funding from NHLBI. M.B. reported receiving grant funding from the NHLBI and Hemostasis and Thrombosis Research Society along with personal fees from Janssen for consulting. E.A. reported grant funding from Boehringer Ingelheim and NIH along with participation on data safety monitoring/advisory boards for Bristol Myers Squibb and Pfizer. C.D.T. reported institutional grant funding from Johns Hopkins All Children's Research Institute and the American Thrombosis and Hemostasis Network (steering committee member). C.T. reported receiving personal fees from Takeda and Sanofi for role on advisory boards. S.A. reported receiving personal fees from Pfizer, Bayer, and Hemabiologics for role on advisory boards. C.M. reported receiving personal fees from Anthos, Astra Zeneca, Bayer, Chiesi, Janssen, and Norgine for consulting. S.S. reported receiving grants from Octapharma and receiving personal fees from Hemostasis Reference Laboratory, Servier, Alexion, Boehringer Ingelheim, Bayer, Sanofi, Daiichi-Sankyo, Regeneron, and Takeda. N.A.G. reported receiving personal fees from Anthos, Astra Zeneca, Bristol Myers Squibb, Bayer, Daiichi-Sankyo, Pfizer, and Novartis. M.M., A.M., J.F., and S.N. had no conflict of interest to report.
Databáze: MEDLINE